GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » LT-Debt-to-Total-Asset

GENE (Genetic Technologies) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Genetic Technologies's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

Genetic Technologies's long-term debt to total assets ratio declined from Jun. 2023 (0.02) to Jun. 2024 (0.00). It may suggest that Genetic Technologies is progressively becoming less dependent on debt to grow their business.


Genetic Technologies LT-Debt-to-Total-Asset Historical Data

The historical data trend for Genetic Technologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies LT-Debt-to-Total-Asset Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 - 0.02 0.02 -

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - - -

Genetic Technologies LT-Debt-to-Total-Asset Calculation

Genetic Technologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (A: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2024 )/Total Assets (A: Jun. 2024 )
=0.015/4.108
=0.00

Genetic Technologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=0.015/4.108
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Technologies  (NAS:GENE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Genetic Technologies LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Technologies Business Description

Traded in Other Exchanges
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.